This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low- to intermediate-grade (Grade 1 or Grade 2), well-differentiated NETs.~The study will enroll 4 cohorts of varying NETs, as follows:~Cohort A - NET of lung origin~Cohort B - NET of small bowel origin~Cohort C - NET of non-small bowel, non-pancreas, and non-lung origin~Cohort D - NET of any origin (DDI substudy)~All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days starting on Cycle 1 Day 1.
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).